| Issue Date | Title | Author(s) |
| 19-Jan-2024 | Editorial: Objective and measurable predictors of violence risk and outcome among forensic patients with psychosis | Sen, P; Kumari, V |
| 1-Feb-2024 | Awareness about developmental coordination disorder | Steenbergen, B; Valtr, L; Dunford, C; Prunty, M; Bekhuis, H; Temlali, TY; van Abswoude, F; Lust, JM; Warlop, G; Augustijn, M; Smits-Engelsman, BCM; Wilson, PH |
| 17-Feb-2024 | Alterations in Genome Organization in Lymphoma Cell Nuclei due to the Presence of the t(14;18) Translocation | Garimberti, E; Federico, C; Ragusa, D; Bruno, F; Saccone, S; Bridger, JM; Tosi, S |
| 20-Feb-2024 | Remote pulmonary rehabilitation for interstitial lung disease: developing the model using experience-based codesign | Brighton, LJ; Spain, N; Gonzalez-Nieto, J; Ingram, KA; Harvey, J; Man, WD-C; Nolan, CM |
| 30-Jan-2024 | In Silico and In Vitro Mapping of Receptor-Type Protein Tyrosine Phosphatase Receptor Type D in Health and Disease: Implications for Asprosin Signalling in Endometrial Cancer and Neuroblastoma | Orton, S; Karkia, R; Mustafov, D; Gharanei, S; Braoudaki, M; Filipe, A; Panfilov, S; Saravi, S; Khan, N; Kyrou, I; Karteris, E; Chatterjee, J; Randeva, HS |
| 23-Feb-2024 | Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies | Cicirò, Y; Ragusa, D; Sala, A |
| 28-Feb-2024 | Tackling physical inactivity and inequalities: implementing a whole systems approach to transform community provision for disabled people and people with long-term health conditions | Pettican, A; Southall-Edwards, R; Reinhardt, GY; Gladwell, V; Freeman, P; Low, W; Copeland, R; Mansfield, L |
| 18-Jan-2024 | Marriage and Culture Around the World: Marrying Someone from a Different Race, Religion, or Nationality | Gaines, SO |
| 23-Feb-2024 | Highly Superior Autobiographical Memory (HSAM): A Systematic Review | Talbot, J; Convertino, G; De Marco, M; Venneri, A; Mazzoni, G |
| 5-Feb-2024 | Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial | Brittain, G; Petrie, J; Duffy, KEM; Glover, R; Hullock, K; Papaioannou, D; Roldan, E; Beecher, C; Bursnall, M; Ciccarelli, O; Coles, AJ; Cooper, C; Giovannoni, G; Gabriel, I; Kazmi, M; Kyriakou, C; Nicholas, R; Paling, D; Peniket, A; Scolding, N; Silber, E; de Silva, T; Venneri, A; Walters, SJ; Young, C; Muraro, PA; Sharrack, B; Snowden, JA |
